Day One Biopharmaceuticals Inc. has released its financial results for the second quarter of 2025, reporting a significant increase in OJEMDA™ (tovorafenib) net product revenue, which reached $33.6 million, up from $8.2 million in the same period of 2024. This represents a quarter-over-quarter growth of 10%. The company has provided a full-year 2025 revenue outlook for OJEMDA, expecting it to range between $140 million and $150 million. The company's net loss for the second quarter of 2025 was reported at $30.3 million, which includes a non-cash stock-based compensation expense of $10.9 million. This contrasts with a net loss of $4.4 million for the same quarter in 2024, which included a gain from the sale of a priority voucher amounting to $108.0 million. Day One also disclosed a decrease in research and development expenses, which totaled $36.1 million in Q2 2025, down from $92.1 million in Q2 2024. The substantial decrease is primarily attributed to the previous year's upfront payment related to the MabCare Therapeutics license agreement. Selling, general, and administrative expenses were slightly lower at $29.0 million compared to $30.2 million in the previous year, mainly due to reduced employee compensation costs. The company's cash, cash equivalents, and short-term investments stood at $453.1 million as of June 30, 2025. In a key corporate development, Michael Vasconcelles, M.D., an industry veteran with over 25 years of oncology research and development experience, joined Day One as Head of Research and Development in June 2025.